<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419729</url>
  </required_header>
  <id_info>
    <org_study_id>39495014.0.0000.0082</org_study_id>
    <nct_id>NCT02419729</nct_id>
  </id_info>
  <brief_title>Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy</brief_title>
  <official_title>Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty-five women will be included in a double-blind randomized trial in order to compare
      fractional CO2 laser treatment, local estrogen therapy and the combination of both treatments
      for Vulvovaginal Atrophy (VVA) and determine the efficacy and possible adverse effects CO2
      laser treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvovaginal atrophy (VVA) symptoms are strongly associated with declining ovarian function
      and estrogen levels in postmenopausal women, having a considerable impact on women's life
      quality. Topical hormonal therapy and hormonal replacement are widely used to alleviate VVA
      symptoms. In this context, minimal invasive fractional CO2 laser emerges as an alternative
      non-hormonal therapy, especially in patients that present contraindications to hormonal
      therapy. Objective: Compare fractional CO2 laser treatment, local estrogen therapy and the
      combination of both treatments for VVA and determine the efficacy and possible adverse
      effects CO2 laser treatment. Materials and Methods: Forty-five postmenopausal women will be
      randomized in three double-blinded groups of treatment consisting of CO2 laser and placebo of
      estrogen vaginal cream, placebo of CO2 laser and estrogen vaginal cream and CO2 laser and
      estrogen vaginal cream. Assessment of baseline characteristics and follow-up will be obtained
      through self-completion questionnaires (Female Sex Function Index, International Consultation
      on Incontinence Questionnaire-Short Form (ICIQ-SF), Vulvovaginal Symptom Questionnaire and
      The Menopause-Specific Quality of Life (MENQOL)). Frost Index and Vaginal Health Index (VHI)
      are part of objective clinical and histologic analyses. Colposcopy, vaginal cytology and
      middle third lateral vaginal wall biopsy will also be performed at baseline and at week 17.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Vulvovaginal Symptom Questionnaire</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>Vulvovaginal Symptom Questionnaire will be used to evaluate improvement of vulvovaginal atrophy symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal Cytology Improvement</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>Vaginal cytology will be obtained from the middle third lateral vaginal wall in order to evaluate initial conditions of the vaginal wall and modifications after treatment. Frost Index, Karyopyknotic Index and Eosinophilic Index will be applied to each sample to measure improvement of vaginal atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sex Function Index</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>Female Sex Function Index will be used to evaluate improvement of vulvovaginal atrophy symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in The Menopause-Specific Quality of Life</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>The Menopause-Specific Quality of Life will be used to evaluate improvement of vulvovaginal atrophy symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary Incontinence Improvement</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>Incontinence Questionnaire-Short Form (ICIQ-SF) will be used in order to evaluate urinary incontinence improvement after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vaginal Health Index Improvement</measure>
    <time_frame>Baseline, week 10 and week 17</time_frame>
    <description>Evaluation of vaginal wall conditions such as pH, elasticity, bleeding signs, secretion type and consistency and hydration.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>CO2 laser &amp; Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effective fractional CO2 laser therapy and effective estrogen vaginal cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO2 laser &amp; Placebo of Estrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of CO2 laser &amp; Estrogen</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 laser</intervention_name>
    <description>SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)</description>
    <arm_group_label>CO2 laser &amp; Estrogen</arm_group_label>
    <arm_group_label>CO2 laser &amp; Placebo of Estrogen</arm_group_label>
    <other_name>Fractionated CO2 laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen</intervention_name>
    <description>Topical estrogen cream treatment: Estriol 1mg daily.</description>
    <arm_group_label>CO2 laser &amp; Estrogen</arm_group_label>
    <arm_group_label>Placebo of CO2 laser &amp; Estrogen</arm_group_label>
    <other_name>Estriol 1mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Estrogen</intervention_name>
    <description>Placebo of topical estrogen cream.</description>
    <arm_group_label>CO2 laser &amp; Placebo of Estrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo of CO2 laser</intervention_name>
    <description>SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.</description>
    <arm_group_label>Placebo of CO2 laser &amp; Estrogen</arm_group_label>
    <other_name>SMARTXIDE2 V2LR - Monalisa Touch - Deka Laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45-65 women with amenorrhea for over 24 months.

          -  Clinical vaginal atrophy diagnosis.

        Exclusion Criteria:

          -  BMI &gt; 35.

          -  Previous use of oral estrogen therapy in the last 6 months.

          -  History or current diagnosis of cancer.

          -  Altered cervical smear in the last 12 months.

          -  Renal or hepatic insufficiency.

          -  Drug-induced menopause.

          -  Previous use of steroids.

          -  Previous vaginal radiotherapy therapy.

          -  Vulvovaginitis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera L da Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Atencao a Saude da Mulher</name>
      <address>
        <city>Sao Bernardo</city>
        <state>Sao Paulo</state>
        <zip>09770-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U. Sexual function after fractional microablative COâ‚‚ laser in women with vulvovaginal atrophy. Climacteric. 2015 Apr;18(2):219-25. doi: 10.3109/13697137.2014.975197. Epub 2014 Dec 16.</citation>
    <PMID>25333211</PMID>
  </results_reference>
  <results_reference>
    <citation>Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet. 2005 Feb;88(2):222-8.</citation>
    <PMID>15779109</PMID>
  </results_reference>
  <results_reference>
    <citation>Bachman GA. A new option for managing urogenital atrophy in post-menopausal women. Cont Obstet Gynecol 42, pp. 13-28.</citation>
  </results_reference>
  <results_reference>
    <citation>Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014 Aug;17(4):363-9. doi: 10.3109/13697137.2014.899347. Epub 2014 Jun 5.</citation>
    <PMID>24605832</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Vera Lucia</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vulvovaginal atrophy</keyword>
  <keyword>Menopause</keyword>
  <keyword>Fractional CO2 laser</keyword>
  <keyword>Estrogen cream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

